Evidence map›Paper›PMID 39910404›Full record

ArticleJournal of cheminformatics2025

Barlow Twins deep neural network for advanced 1D drug-target interaction prediction.

Maximilian G Schuh, Davide Boldini, Annkathrin I Bohne, Stephan A Sieber

Abstract read
In one paragraph

Article in Journal of cheminformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maximilian G SchuhChair of Organic Chemistry II, Department of Bioscience, TUM School of Natural Sciences, Center for Functional Protein Assemblies (CPA), Technical University of Munich, Ernst-Otto-Fischer Str. 8, 85748, Garching bei München, Bavaria, Germany.ORCID https://orcid.org/0009-0008-2415-8810
Davide BoldiniChair of Organic Chemistry II, Department of Bioscience, TUM School of Natural Sciences, Center for Functional Protein Assemblies (CPA), Technical University of Munich, Ernst-Otto-Fischer Str. 8, 85748, Garching bei München, Bavaria, Germany. davide.boldini@tum.de.
Annkathrin I BohneChair of Biochemistry, Department of Bioscience, TUM School of Natural Sciences, Center for Functional Protein Assemblies (CPA), Technical University of Munich, Ernst-Otto-Fischer Str. 8, 85748, Garching bei München, Bavaria, Germany.ORCID https://orcid.org/0009-0001-9557-663X
Stephan A SieberChair of Organic Chemistry II, Department of Bioscience, TUM School of Natural Sciences, Center for Functional Protein Assemblies (CPA), Technical University of Munich, Ernst-Otto-Fischer Str. 8, 85748, Garching bei München, Bavaria, Germany. stephan.sieber@tum.de.ORCID https://orcid.org/0000-0002-9400-906X

Funding

European Research Council breakingBAC, 101096911Merck KGaA Darmstadt Merck Future Insight Prize 2020
6 · The paper itself

Abstract

Accurate prediction of drug-target interactions is critical for advancing drug discovery. By reducing time and cost, machine learning and deep learning can accelerate this laborious discovery process. In a novel approach, BarlowDTI, we utilise the powerful Barlow Twins architecture for feature-extraction while considering the structure of the target protein. Our method achieves state-of-the-art predictive performance against multiple established benchmarks using only one-dimensional input. The use of our hybrid approach of deep learning and gradient boosting machine as the underlying predictor ensures fast and efficient predictions without the need for substantial computational resources. We also propose the use of an influence method to investigate how the model reaches its decision based on individual training samples. By comparing co-crystal structures, we find that BarlowDTI effectively exploits catalytically active and stabilising residues, highlighting the model's ability to generalise from one-dimensional input data. In addition, we further benchmark new baselines against existing methods. Together, these innovations improve the efficiency and effectiveness of drug-target interactions predictions, providing robust tools for accelerating drug development and deepening the understanding of molecular interactions. Therefore, we provide an easy-to-use web interface that can be freely accessed at https://www.bio.nat.tum.de/oc2/barlowdti . SCIENTIFIC CONTRIBUTION: Our computationally efficient and effective hybrid approach, combining the deep learning model Barlow Twins and gradient boosting machines, outperforms state-of-the-art methods across multiple splits and benchmarks using only one-dimensional input. Furthermore, we advance the field by proposing an influence method that elucidates model decision-making, thereby providing deeper insights into molecular interactions and improving the interpretability of drug-target interactions predictions.

Indexed as

Deep neural networkDrug discoveryDrug–target interactionsMachine learning

Identifiers

PMID39910404
PMCPMC11800607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.